Abstract

ObjectivesMany trials have shown that intensive management is effective in patients with early active rheumatoid arthritis (RA). But its benefits are unproven for the large number of RA patients seen in routine care who have established, moderately active RA and are already taking conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs). The TITRATE trial studied whether these patients also benefit from intensive management and, in particular, achieve more remissions. MethodsA 12-month multicentre individually randomised trial compared standard care with monthly intensive management appointments which was delivered by specially trained healthcare professionals and incorporated monthly clinical assessments, medication titration and psychosocial support. The primary outcome was 12-month remission assessed using the Disease Activity Score for 28 joints using ESR (DAS28-ESR). Secondary outcomes included fatigue, disability, harms and healthcare costs. Intention-to-treat multivariable logistic- and linear regression analyses compared treatment arms with multiple imputation used for missing data. Results459 patients were screened and 335 were randomised (168 intensive management; 167 standard care); 303 (90%) patients provided 12-month outcomes. Intensive management increased DAS28-ESR 12-month remissions compared to standard care (32% vs 18%, p = 0.004). Intensive management also significantly increased remissions using a range of alternative remission criteria and increased patients with DAS28-ESR low disease activity scores. (48% vs 32%, p = 0.005). In addition it substantially reduced fatigue (mean difference -18; 95% CI: -24, -11, p<0.001). There was no evidence that serious adverse events (intensive management =15 vs standard care =11) or other adverse events (114 vs 151) significantly increase with intensive management. InterpretationThe trial shows that intensive management incorporating psychosocial support delivered by specially trained healthcare professions is effective in moderately active established RA. More patients achieve remissions, there were greater improvements in fatigue, and there were no more harms.

Highlights

  • We proposed rejecting the null hypothesis if remission rate increased by 15%

  • Total costs and quality-adjusted life years were measured using the EuroQol and combined to assess the health economic effects of intensive management compared with standard care, which was represented by an incremental cost-effectiveness ratio, see (Supplementary Table 3).TagedEn

  • TagedPAn additional exploratory analysis showed that patients who had 11 or 12 intensive management visits achieved the best outcomes in terms of remissions and falls in 12-month DAS28-ESR, pain and fatigue scores (Online Supplementary Figure).TagedEn

Read more

Summary

City Research Online

B., Georgopoulou, S., Martin, N., Neatrour, I., Nikiphorou, E., Sturt, J., Wailoo, A., Williams, F. M. K., Williams, R. and Lempp, H. The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial. Seminars in Arthritis and Rheumatism, 50(5), pp. This is the published version of the paper. URLs from City Research Online may be freely distributed and linked to. Reuse: Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way

Contents lists available at ScienceDirect
Objectives
TagedEn TagedFiur
Clinical Assessments
Sulfasalazine Subcut
None One DMARDs Two DMARDs Etanercept Benepali Other TNF Inhibitor
Remission Classification Intensive Management Standard Care
Mixed Effect Models
Findings
Ruptured thoracic aneurysm Metastatic cancer À
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call